Umlaut.Bio
Umlaut.Bio is a spinout of the EMBL, is pursuing tRNA targets for treatment of cancer and immunological diseases.
$3.46M Pre Seed ·
Source: N24 Haber
Funding history ↓Signals
Website registeredMay 13, 2022 (4 years old)
Funding rounds
Timeline
- Website created
Companies like Umlaut.Bio
OOna Therapeutics$86.6M Series B+ · Oct 2026
RRevolver Therapeutics$763.3K Pre Seed · Jul 2026
CCrossbow Therapeutics$77M Series B+ · Mar 2026
AA2 Biotherapeutics$80M Series B+ · Jan 2025
NNomosPre Seed · Oct 2024TTippingPoint Biosciences$4.5M Seed · Mar 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/umlaut-bio (get a free API key).